Literature DB >> 19672768

The role of toll-like receptors in chronic B-cell malignancies.

Marta Muzio1, Maria T S Bertilaccio, Giorgia Simonetti, Michela Frenquelli, Federico Caligaris-Cappio.   

Abstract

Toll-like receptors (TLR) are key players in host defence from infection. They recognize a specific set of molecular patterns of microbial origin, immediately trigger an innate immune response, and bridge innate and adaptive immunity. TLR have also been shown to play a role in tumor development. In this context, chronic B-cell malignancies are an interesting example as clonal B lymphocytes remain responsive to and dependent on stimuli originating from the microenvironment which then become crucial for maintaining and propagating the disease. Emerging evidences suggest that, among other microenvironmental elements, TLR ligands may play a role in the pathogenesis of chronic B-cell lymphoid malignancies. Conceivably, their manipulation may find a place in specific settings of treatment of these tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19672768     DOI: 10.1080/10428190903115410

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

1.  Dysregulated B-cell TLR2 expression and elevated regulatory B-cell frequency precede the diagnosis of AIDS-related non-Hodgkin lymphoma.

Authors:  Basile Siewe; Joey T Pham; Mardge Cohen; Nancy A Hessol; Alexandra Levine; Otoniel Martinez-Maza; Alan Landay
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

2.  Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

Authors:  Sarah E M Herman; Rashida Z Mustafa; Jennifer A Gyamfi; Stefania Pittaluga; Stella Chang; Betty Chang; Mohammed Farooqui; Adrian Wiestner
Journal:  Blood       Date:  2014-03-21       Impact factor: 22.113

3.  TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.

Authors:  Adrian Wiestner; Sarah E M Herman; Eman L Dadashian; Erin M McAuley; Delong Liu; Arthur L Shaffer; Ryan M Young; Jessica R Iyer; Michael J Kruhlak; Louis M Staudt
Journal:  Cancer Res       Date:  2018-11-29       Impact factor: 12.701

4.  Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.

Authors:  Jooeun Bae; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi
Journal:  Br J Haematol       Date:  2011-09-09       Impact factor: 6.998

5.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

6.  Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.

Authors:  Crystina L Kriss; Javier A Pinilla-Ibarz; Adam W Mailloux; John J Powers; Chih-Hang Anthony Tang; Chang Won Kang; Nicola Zanesi; Pearlie K Epling-Burnette; Eduardo M Sotomayor; Carlo M Croce; Juan R Del Valle; Chih-Chi Andrew Hu
Journal:  Blood       Date:  2012-06-12       Impact factor: 22.113

7.  TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

Authors:  Qifang Zhang; Dewan Md Sakib Hossain; Sergey Nechaev; Anna Kozlowska; Wang Zhang; Yong Liu; Claudia M Kowolik; Piotr Swiderski; John J Rossi; Stephen Forman; Sumanta Pal; Ravi Bhatia; Andrew Raubitschek; Hua Yu; Marcin Kortylewski
Journal:  Blood       Date:  2013-01-03       Impact factor: 22.113

8.  TLR2-activated B cells are phenotypically similar to the abnormal circulating B cells seen preceding the diagnosis of AIDS-related NHL diagnosis.

Authors:  Yu Guo; Basile Siewe; Marta Epeldegui; Roger Detels; Alan L Landay; Otoniel Martínez-Maza
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

9.  Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients.

Authors:  Reem Karmali; Laura A Paganessi; Robin R Frank; Sucheta Jagan; Melissa L Larson; Parameswaran Venugopal; Stephanie A Gregory; Kent W Christopherson
Journal:  J Leukoc Biol       Date:  2012-11-07       Impact factor: 4.962

Review 10.  Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8.

Authors:  Martina Molgora; Domenico Supino; Alberto Mantovani; Cecilia Garlanda
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.